-

Shareholder Alert: Robbins LLP is Investigating Cabot Oil and Gas Corporation (COG) on Behalf of Shareholders

SAN DIEGO & HOUSTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Cabot Oil and Gas Corporation (NYSE: COG) for breaches of fiduciary duties and violations of the Securities and Exchange Act of 1934 for wrongdoing beginning in October 2015. Cabot is an independent oil and gas company primarily operating in Pennsylvania's Marcellus Shale.

If you have suffered a loss due to Cabot Oil and Gas Corporation's misconduct, click here.

Cabot Oil and Gas Corporation (COG) Failed to Fix Faulty Gas Wells and the Resulting Water Pollution

Cabot has a history of polluting Pennsylvania's water supplies, endangering citizens, and facing governmental scrutiny for its environmental liabilities. On February 27, 2017, Cabot filed with the SEC a Form 10-K for fiscal year ended December 31, 2016, disclosing that it had entered into a Consent Order and Agreement with the Pennsylvania Department of Environmental Protection (PaDEP) on December 30, 2016, relating to gas migration allegations in an area surrounding several wells owned and operated by Cabot in Susquehanna County and agreeing to pay a civil monetary penalty of $300,000.

On July 26, 2019, Cabot filed a Form 10-Q for the quarter ending June 30, 2019, disclosing that the company had received two notices of violation from the PaDEP in June and November of 2017, for failing to prevent the migration of gas into local fresh groundwater sources, which had exposed the Company to civil monetary penalty. On this news, Cabot's shares fell 12.07% the same day. Then, on June 15, 2020, following a grand jury investigation, the PA attorney general's office charged Cabot with fifteen criminal counts related to the company's failure to fix faulty gas wells and the resulting water pollution. On this news, Cabot's shares fell 3.34%, closing at $19.40 per share on June 15, 2020. The stock has yet to recover.

Cabot Oil and Gas Corporation (COG) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Cabot settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Nano-X Imaging Ltd. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026. Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Al...

Investor Notice: Robbins LLP Informs Investors of the ADMA Biologics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.For more information, submit...

Investor Notice: Robbins LLP Informs Investors of the Erasca, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...
Back to Newsroom